NuVasive Inc (NUVA) Raising PT on Accretive Acquisition - Brean Capital
Get Alerts NUVA Hot Sheet
Rating Summary:
11 Buy, 21 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE
Brean Capital analyst, Jason Wittes, raised his PT ON NuVasive (NASDAQ: NUVA) to $60 from $58. Last night, after the close NUVA acquired privately held Biotronic NeuroNetwork, a neuro monitoring service business for $98 million or roughly 2x 2015 sales of $50 million. This doubles the size of NUVA’s current neuro-monitoring service business (Intra-Operative Monitoring (IOM), another regional player, which it originally acquired in 2011 for $80 million representing roughly 2-3x sales trailing 12 months and 2x its $40 million run rate at the time of acquisition). The deal is expected to close in early July and is expected to be immediately accretive both in terms of EPS and EBITDA--adding potentially a nickel to EPS in 2016. There is very little overlap (Biotronic is a regional player with strength mainly in Chicago), and the deal appears largely plug and play.
No change to Buy rating.
For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.
Shares of NuVasive closed at $57.37 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Safran SA (SAF:FP) (SAFRY) PT Raised to EUR211 at Citi, 'remain positive on the aftermarket'
- AO World Plc. (AO/:LN) PT Raised to GBP1.25 at Jefferies
- Now Inc (DNOW) PT Raised to $18 at Stifel
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
Definitive Agreement, Brean CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!